Pharmacogenetics and the future of medical practice

British Journal of Clinical Pharmacology

Volumn 54, Issue 2, 2002, Pages 221-230

  Lindpaintner, Klaus ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Drug response; Genetics; Pharmacogenetics; Pharmacogenomics; Pharmacology

Indexed keywords

HERCEP TIN; TRASTUZUMAB;

CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; DNA POLYMORPHISM; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; MEDICAL ETHICS; MEDICAL PRACTICE; MEDICINE; MOLECULAR GENETICS; NONHUMAN; PALLIATIVE THERAPY; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

DRUG DESIGN; FORECASTING; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

EID: 0036040770     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01630.x     Document Type: Conference Paper

References (23)

1. Drug disposition: To phenotype or genotype
2. Pharmacogenomics: Translating functional genomics into rational therapies
3. Phase II study of weekly intravenous recombinant humanized anti-p185 (HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
4. Not quite pharmacogenomics
5. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription
6. Polymorphisms of the 5′ leader cistron of the human beta2-adrenergic receptor regulate receptor expression
7. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression
8. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion of the CKR5 structural gene
9. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene
10. HIV-1 infection in a man homozygous for CCR5 32
11. HIV-1 infection in an individual homozygous for CCR5 32
12. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment
13. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing
14. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics
15. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties
16. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells
17. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects
18. 2-adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population
19. Genetic factors in aminoglycoside toxicity
20. Proposed molecular and cellular mechanism for aminoglycoside ototoxicity
21. Inactivation of the DNA-repair gene mgmt and the clinical response of gliomas to alkylating agents
22. Pharmacogentics and future drug development and delivery